Therapy with lenalidomide plus dexamethasone-induced bone formation in a patient with refractory multiple myeloma

[1]  G. Roodman,et al.  Myeloma bone disease: Pathophysiology and management , 2013, Journal of bone oncology.

[2]  M. Dimopoulos,et al.  Advances in imaging and the management of myeloma bone disease. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  U. Mellqvist,et al.  Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement , 2011, Leukemia.

[4]  M. Dimopoulos,et al.  The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group , 2010, Leukemia.

[5]  M. Dimopoulos,et al.  Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  F. Dammacco,et al.  Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide. , 2010, Leukemia research.

[7]  H. Asaoku,et al.  Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. , 2008, International journal of oncology.

[8]  M. Dimopoulos,et al.  The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma , 2007, Leukemia.

[9]  D. Esseltine,et al.  Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma , 2005, British journal of haematology.

[10]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.